Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 1/20 | 0.46 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.45 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | TYMS | P04818 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9280377 | 0.79 | CFTR (0.49) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL9502317 | 0.77 | SMN1; SMN2 (0.47) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL9975204 | 0.77 | CFTR (0.46) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL9879489 | 0.77 | CFTR (0.46) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11848675 | 0.75 | CFTR (0.47) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL11480489 | 0.72 | ALPL (0.41) | MEN1KMT2ATDP1ALDH1A1CYP3A4 | |
| SCHEMBL6271326 | 0.72 | NPSR1 (0.49) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL21325292 | 0.72 | NPSR1 (0.49) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| SCHEMBL29502553 | 0.72 | NPSR1 (0.49) | CFTRGOPCLMNAMAPTSMN1; SMN2 | |
| Acetic Acid SCHEMBL9529275 | 0.72 | SMN1; SMN2 (0.47) | CFTRGOPCLMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-55047679-A | — | — | None | — | — | JP | disclosed |
| JP-55043025-A | — | — | None | — | — | JP | disclosed |
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | BAYER SCHERING PHARMA AG (DE) | 2008-06-19 | — | — | US | disclosed |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | BAYER SCHERING PHARMA AG (DE) | 2008-05-29 | — | — | US | disclosed |
| EP-1903037-A1 | 1-(hetero)aryl-3-[heteroaryl-piperidin-4yl]-thiourea derivatives as modulators of EP2 receptors | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-26 | — | — | EP | disclosed |
| EP-1900731-A1 | N-(1-Phthalazin-1-yl-piperidin-4-yl)-amides as EP2-receptor modulators | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-03-19 | — | — | EP | disclosed |
| WO-2008028690-A1 | 1-(HET)ARYL-3-[HETARYL-PIPERIDIN-4-YL]-THIOUREAS AS MODULATORS OF THE EP2 RECEPTOR | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| WO-2008028689-A1 | N-(1-PHTHALAZIN-1-YLPIPERIDIN-4-YL)AMIDES AS EP2 RECEPTOR MODULATORS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-03-13 | — | — | WO | disclosed |
| JP-S5547679-A | NOVEL 4-ALKYL-2-PYRIDYL-1-PHTHALAZONE DERIVATIVE | ISHIKAWA MASAYUKI | 1980-04-04 | — | — | JP | disclosed |
| JP-S5543025-A | NOVEL 4-ALKYL-2-PHENYL-1-PHTHALAZONE DERIVATIVE | ISHIKAWA MASAYUKI | 1980-03-26 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146576-A1 | N-(1-Phthalazin-1-ylpiperidin-4-yl)amides as EP2 receptor modulators | PTGER2, PTGER1, PTGDR2 | CFTR 1161/4885GOPC 3468/4885LMNA 2361/4885 |
| US-20080125435-A1 | 1-(Het)aryl-3-[hetaryl-piperidin-4-yl]-thioureas as modulators of the EP2 receptor | PTGER2, PTGER1, PTGES2 | CFTR 202/4885GOPC 4291/4885LMNA 4575/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.